# GLOW Peptide: GHK-Cu, BPC-157, and TB-500 in the Research Literature

> GLOW peptide is a three-constituent research blend of GHK-Cu, BPC-157, and TB-500, studied for collagen signaling, angiogenesis, tissue repair, and anti-aging mechanisms. A literature digest.

## What Is GLOW Peptide?

GLOW peptide is a three-peptide research blend combining GHK-Cu (glycyl-L-histidyl-L-lysine copper tripeptide), BPC-157 (a 15-amino-acid gastric-derived synthetic peptide), and TB-500 (a synthetic fragment of Thymosin Beta-4). Each constituent is studied separately in the published preclinical and clinical literature. No controlled trial has examined the combination as a single formulation [23].

GHK-Cu is an endogenous human tripeptide found in plasma, saliva, and urine. Plasma levels decline from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60 — a 60% reduction coinciding with measurable decline in skin regenerative capacity [1]. At nanomolar concentrations (1–10 nM), GHK-Cu stimulates collagen and glycosaminoglycan synthesis while modulating matrix metalloproteinase (MMP) and TIMP activity in dermal fibroblasts [2].

BPC-157 — Body Protective Compound 157 — is a 15-amino-acid synthetic pentadecapeptide derived from a protein in human gastric juice, with documented stability in gastric acid for more than 24 hours. In rodent wound models at doses of 10 µg/kg, 10 ng/kg, and 10 pg/kg, BPC-157 consistently accelerated wound re-epithelialization, reduced inflammatory infiltration, and improved collagen organization across incisional, excisional, burn, and diabetic ulcer models [13].

TB-500 is a synthetic fragment of Thymosin Beta-4, the major G-actin-sequestering molecule in eukaryotic cells. By maintaining a pool of unpolymerized actin, it enables rapid cytoskeletal reorganization during cell migration — a prerequisite for wound closure. Separately, TB-500 directly inhibits NF-kB RelA/p65 nuclear translocation, suppressing IL-8 and other pro-inflammatory cytokines independent of its actin-binding function [18]. Thymosin Beta-4, the parent protein, is the only GLOW constituent with Phase 2 human wound-healing trial data [20].

The combination rationale is mechanistic: GHK-Cu addresses collagen and ECM gene expression, BPC-157 addresses angiogenesis and fibroblast priming, and TB-500 enables cell migration and inflammatory resolution. Whether these mechanisms amplify each other in a combined protocol is a question without a published answer.

## What Does the GLOW Peptide Do?

GLOW peptide targets three axes of skin and tissue repair studied extensively in preclinical models: collagen and extracellular-matrix (ECM) remodeling, vascular support and angiogenesis, and inflammatory resolution.

On the collagen axis: GHK-Cu at 1–10 nM upregulated collagen I, dermatan sulfate, chondroitin sulfate, and decorin in human dermal fibroblasts while simultaneously modulating MMP-2 activation with TIMP-1/TIMP-2 inhibition — balancing matrix synthesis and breakdown rather than simply accelerating either [2]. A randomized clinical trial (n=40 female volunteers, ages 40–65, 8 weeks) found GHK-Cu in a nano-carrier formulation reduced wrinkle volume by 55.8% (p<0.001) and wrinkle depth by 32.8% (p=0.012) vs control serum, with confirmed collagen and elastin upregulation [4].

On the vascular axis: BPC-157 promotes angiogenesis by upregulating VEGFR2 receptor expression — not VEGF-A itself — and activating the downstream VEGFR2-Akt-eNOS signaling cascade. This was demonstrated in CAM assay, tube formation assay, and rat hind-limb ischemia model, with enhanced blood flow recovery and vessel density vs controls [12].

On the inflammatory axis: TB-500's direct inhibition of NF-kB RelA/p65 nuclear translocation suppresses IL-8 and pro-inflammatory cytokines via a mechanism distinct from its actin-sequestering function [18]. GHK-Cu reinforces this via Nrf2 antioxidant pathway activation and NFkB suppression [6].

No study has measured the combined effect of all three acting simultaneously.

## What Is GLOW Peptide Used For in Research?

The GLOW blend has been studied — at the constituent level — for four primary research applications: collagen production and skin remodeling, wound healing and tissue repair, hair follicle cycling and growth, and anti-inflammatory signaling.

Skin remodeling is the most clinically evidenced application. GHK-Cu has produced statistically significant reductions in wrinkle depth and volume in multiple human clinical trials, and outperformed vitamin C (50%) and retinoic acid (40%) for procollagen synthesis in 70% of subjects in a one-month comparative study [5]. These are topical application results; injectable GHK-Cu has a separate, smaller evidence base.

Wound healing spans all three constituents. BPC-157 at picogram-level doses improved granulation tissue maturation and reduced inflammation in diabetic wound models, outperforming PDGF-BB/becaplermin in collagen organization [13]. Thymosin Beta-4 accelerated re-epithelialization 42–61% in rat full-thickness wound models and stimulated keratinocyte migration 2–3-fold in vitro at as little as 10 picograms [17].

Hair follicle research is primarily GHK-Cu and TB-500. GHK-Cu stimulated follicle size, upregulated VEGF and FGF, and produced visible growth indicators within 10 days of intradermal injection in a clinical study [8]. In a randomized, double-blind trial (n=45), a GHK complex increased hair count by 52.6–71.5 strands per group vs 9.6 for placebo (p<0.05) [9]. TB-500 (Thymosin Beta-4) doubled follicle growth in rats within 7 days of topical application [19].

The [GLOW peptide dosage](/dosage) and [GLOW peptide benefits](/benefits) pages cover each application category in greater depth.

## Peptide Blend and Skin Repair: How the Three Work Together

The theoretical rationale for combining GHK-Cu, BPC-157, and TB-500 is that each addresses a different rate-limiting step in cutaneous repair. GHK-Cu signals fibroblasts to reset gene expression toward a younger, more repair-competent profile — affecting approximately 31.2% of all human genes, with 59% upregulated and 41% suppressed [3]. BPC-157 ensures the vascular supply: VEGFR2 upregulation drives angiogenesis that delivers oxygen and nutrients to healing tissue [12]. TB-500 enables the cellular workforce: G-actin sequestration frees the cytoskeletal machinery that keratinocytes and fibroblasts need to migrate into a wound site [21].

The sequence matters in healing models. Angiogenesis (BPC-157) precedes matrix synthesis (GHK-Cu); cell migration (TB-500) enables re-epithelialization before collagen remodeling can complete. A protocol that addresses all three in parallel is conceptually coherent. Controlled evidence for the specific combination does not exist.

The [research literature overview](/research) covers each constituent's mechanistic data with full citations. The [GHK-Cu copper peptide mechanism](/research#ghk-cu) section details the gene-expression and fibroblast-signaling data in full.

## GLOW Peptide Composition: The Three Constituents

**GHK-Cu** is glycyl-L-histidyl-L-lysine copper(II) — a three-amino-acid tripeptide (MW ~315 Da as free peptide) that forms a high-affinity complex with copper(II) ions. It is an endogenous human peptide found in plasma at ~200 ng/mL at age 20, declining to ~80 ng/mL by age 60 [1]. GHK-Cu for topical cosmetic use has a documented safety record spanning decades. Injectable GHK-Cu lacks a comparable human safety dataset.

**BPC-157** — Body Protective Compound 157 — is a 15-amino-acid synthetic peptide (sequence: GEPPPGKPADDAGLV, MW 1,419 Da) derived from a protein found in human gastric juice [25]. It is stable in gastric acid for more than 24 hours and has been studied via intraperitoneal, oral, topical, and subcutaneous routes in animal models. BPC-157 was classified as an FDA Category 2 bulk drug substance in September 2023, barring its use in compounded medications in the United States. WADA added it to the S0 Non-Approved Substances list in 2022 [22].

**TB-500** is a synthetic peptide fragment corresponding to residues 17–23 of Thymosin Beta-4, a 43-amino-acid protein abundant in platelets and wound-site fluids. TB-500 is prohibited by WADA under S2.3 Growth Factors and Growth Factor Modulators (effective January 2012). It is not FDA-approved for any human clinical indication [23].

What Is GLOW 70? GLOW 70 is a 70 mg vial format of the GLOW blend, a pre-measured compounded formulation combining GHK-Cu, BPC-157, and TB-500 in a single vial per clinic protocol documentation. Clinic documentation describes reconstitution with 3 mL of bacteriostatic water, yielding approximately 23 mg/mL total peptide concentration for dosing calculations. No peer-reviewed publication has validated this vial format or its specific component ratios.

---

An archival digest of the published constituent literature on the GLOW peptide blend — not a clinic, not a vendor, not a prescription.